ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT InhibitorsBusiness Wire • 11/16/23
Retail Stocks are Highlighting This Week's Earnings Lineup but Is it Too Soon to Buy?Zacks Investment Research • 11/16/23
Target Stock Up 17% on This Big News: Here's Why This High-Yield Stock Is Still a BuyThe Motley Fool • 11/15/23
Target expects shoplifting to remain ‘significant financial headwind' despite closing troubled storesNew York Post • 11/15/23
Higher prices aren't helping Target's sales much. That's a good thing, the retailer says.Market Watch • 11/15/23
As Target's stock soars on earnings beat, investors keep an eye on profit marginsMarket Watch • 11/15/23